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Serum levels of natriuretic peptides are well established as important biomarkers in patients
with cardiac disease. Less attention has been placed on the role of natriuretic peptides in
patients with pulmonary conditions. In several well-defined groups of patients with pulmonary
disease natriuretic peptides provide the clinician with clinically valuable information. A limi-
tation of the interpretation of natriuretic peptides in pulmonary disease is the confounding
effect of concurrent conditions such as heart failure, hypoxia, sepsis and renal failure. The
present paper reviews the role of natriuretic peptides for diagnosis, risk stratification and
prognosis of several pulmonary disorders.
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(NPs) was first reported in a murine model by de Bold et al.
in 1981 who demonstrated the potent natriuretic effect of
an extract of atrial tissue.1 This novel compound was called
atrial natriuretic peptide. In 1988 brain natriuretic peptide
(BNP) was isolated from the porcine brain.2 Subsequently
circulating levels of NPs were reported in humans.3 The
clinical value of the measurement of NPs has now been well
established in cardiovascular disease, specifically in the
diagnosis and management of congestive heart failure
(CHF).4e6 Serum levels of NPs are commonly used as
a diagnostic tool in Emergency Room patients presenting
with acute dyspnea to distinguish cardiac from non-cardiac
causes.7 A number of excellent papers have reviewed the
role of NP in cardiovascular disease.4e6 Less attention has
been placed regarding the use of NPs in pulmonary condi-
tions. The present review elucidates the role of NPs for
diagnosis, risk stratification and prognosis of several
pulmonary disorders.NPs physiology
BNP is a biologically active 32 amino acid molecule.8 It is
synthesized predominantly in the cardiac ventricle.9 A
prohormone called pre-proBNP is cleaved into the biologi-
cally active BNP and the inactive NT-proBNP. Recent data
suggest that this is a more complex process, and that many
different low and high molecular weight variants of BNP
might exist in circulation. 10 The main stimulus for secretion
of NPs is myocardial wall stress, with pressure or volume
overload. More recently, pro-inflammatory cytokines and
sympathetic activity have been identified as triggers for
BNP secretion.11,12 This may explain elevated levels of NPs
in patients with normal ventricular function. The NPs bind
to membrane receptors that are coupled to the cyclic
guanosine monophospate intracellular messenger system.13
The biologic effects of NPs include vasodilatation, natri-
uresis and diuresis. In addition, NPs have been reported to
downregulate the renineangiotensinealdosterone system14
and have an anti-fibrotic role in the myocardial cell.15
The clearance of serum NPs involves two pathways:
enzymatic degradation by endopeptidases and receptor
mediated endocytosis. 8 The half-life for BNP is 22 min
while the half-life for NT-proBNP is 120 min.16 Both mole-
cules are currently measured in clinical practice. Both tests
are reliable, have good analytical performance with well-
calibrated cutoff values for the diagnosis of CHF.17 In the
Breathing-Not-Properly trial, a BNP cutoff value of 100 pg/
ml had a high negative predictive value (NPV) while CHF
was very likely at BNP values >500 pg/ml.7 In the “Pro-BNPInvestigation of Dyspnea in the Emergency Department
(PRIDE)” study the best diagnostic threshold was 900 pg/ml,
with a level less than 300 pg/ml being optimal for ruling out
HF.18 NT-proBNP threshold levels are, however, age
dependent. It is important to recognize that the levels of
NPs have an inverse relation with the body mass index,19
therefore the sensitivity of the test decreases in obese
patients. This is probably related to endopeptidases
secreted by the adipose tissue.17 The relation of NPs levels
with renal failure (with or without renal replacement
therapy) is also complicated and non-linear.20Normal values
The currently accepted normal values for NP’s are
described in Table 1. These values were initially selected
for the diagnosis of congestive heart failure. The values
between normal and elevated are what several authors
have called the “grey zone”. Many of the pulmonary
conditions discussed in this paper have NP values within this
intermediate range.Pulmonary embolism
The first case of increased BNP in pulmonary embolism (PE)
was reported in 1997.21 Multiple patient cohorts have
subsequently been studied. Several studies have been
performed in an attempt to correlate increased levels of
NPs with evidence of right ventricular dysfunction. Kruger
et al.22 analyzed 50 consecutive patients with acute PE and
found that a BNP >90 pg/mL was associated with a risk
ratio of 28.4 (95% CI, 3.22e251.12) for the diagnosis of RV
dysfunction by echocardiography. A similar study demon-
strated significant elevations in both BNP and NT-proBNP
when right ventricular dysfunction was detected by
helical computed tomography.23 Two recent meta-anal-
yses24,25 have shown the strong relation between increased
NPs and mortality in PE. The first meta-analysis reported
a strong correlation between the BNP level and death, with
an odds ration of 6.10 (95% CI, 2.58e14.25). In the second
meta-analysis, using a cutoff value of 100 pg/mL for BNP
and 600 pg/mL for NT-proBNP, an odds ratio for all-cause-
mortality of 6.0 (95% CI, 1.31e27.43) was found. Although
high levels of NPs predict adverse outcomes in PE, their role
as a “rule out” test may be more valuable due to their high
negative predictive value of 99% (95% CI, 97e100).24 Vuil-
leumier et al. compared NT-proBNP to others markers for
risk stratification in non-massive PE.26 In this study NT-
proBNP was the strongest predictor for an unfavorable
Table 1 Normal levels for NP’s (pg/mL).
Normal Elevated
BNP <100 >500
NT-proBNP <250 >450 age <50
>900 age 50e75
>1800 age >75
1772 D. Salerno, P.E. Marikoutcome with a negative predictive value of 100% (95% CI,
91e100) when NT-proBNP was less than 300 pg/mL.
Several other roles for the measurement of NPs in the
context of acute and chronic PE are described in the
literature, however, most of the data comes from single
studies. These include the prediction of pulmonary hyper-
tension after acute PE,27 correlation of central vs. periph-
eral PE28 and preoperative and postoperative evaluation of
pulmonary endarterectomy in patients with chronic PE.29Chronic obstructive pulmonary disease
The elevation of serum NPs in patients with chronic
obstructive pulmonary disease (COPD) is much less dramatic
than seen in CHF patients. In a single hospital study30 serum
BNP was measured in 208 consecutive patients with an acute
exacerbation of COPD. The levels were significantly higher at
time of the exacerbation than during recovery (65 pg/mL
[IQR, 34e189 pg/mL] vs. 45 pg/mL [IQR, 25e85 pg/mL];
P< 0.001). More importantly in multivariate analysis there
was a strong association between BNP levels and need of ICU
treatment (HR, 1.13; 95%CI, 1.03e1.24 for an increase inBNP
of 100 pg/mL; PZ 0.008), but there was no significant
correlation of BNP levels with either short or long-term
mortality.30 The authors suggested that part of the eleva-
tion of BNP in this setting could be related to the inflamma-
tory response seen in COPD flares, as has been previously
shown in vitro.31 It is, however, important to note that the
differences between BNP levels in patients with COPD are
much smaller than those seen in patients with CHF. Elevated
NPs in patients’ with COPD may be due to unsuspected
concomitant heart failure32 or significant pulmonary hyper-
tension.33 A small observational cohort of intubated COPD
patients who were difficult to wean showed a significant
increase in NT-proBNP levels in those with acute cardiac
dysfunction during the weaning trial compared to those
without acute cardiac dysfunction.34 Patients with acute
cardiac dysfunction had a NT-proBNP median of 5000 pg/mL
compared to patients without cardiac dysfunction with
a median of 1705 pg/mL. NPs could serve as a surrogate
marker for cardiac dysfunction in this setting.Pulmonary hypertension
Based on its mechanism of transcription and secretion the
NPs would be expected to be increased in patients with
pulmonary hypertension (HTN). In general terms due to the
smaller myocardial mass the elevations of BNP or NT-
proBNP related to right heart dysfunction are smaller than
observed in patients with left heart dysfunction. Never-
theless, NPs could have a role in the early detection of
pulmonary HTN.35 In a study in 44 patients with pulmonaryHTN Nagaya et al.36 showed a significant difference
between those with pulmonary HTN compared to those
without regarding their BNP levels (48 14 pg/mL vs.
294 17 pg/mL P< 0.05); there was also a significant
difference in survival related to the trend in the BNP level
in the group with pulmonary HTN. In several conditions
associated with pulmonary HTN the NPs levels correlate
with the degree of functional impairment.29,37,38 Several
authors39,40 have shown strong correlations between
hemodynamic values and changes in NP levels in patients
with different types of pulmonary HTN. Moreover, many of
the pharmacological interventions used to treat pulmonary
HTN cause a decline in the levels of NPs.20 However, at this
time it is not clear if the NP levels can be used as an aid to
titrate therapy in pulmonary HTN.41,42Acute respiratory distress syndrome
Acute respiratory distress syndrome (ARDS) is associated
with pulmonary hypertension and right ventricular
dysfunction resulting in increased NP levels.35,43 Further-
more, transcription of the BNP gene has been described in
the lung44,45 and it has been suggested that capillary
leakage by itself could locally increase BNP. In addition,
BNP levels are often elevated in ICU patients even without
cardiac dysfunction.46
Many factors are related to the elevation of NPs in ICU
patients, including sepsis and hypoxemia.47,48
Karmpaliotis and colleagues performed right heart
cathetized in 80 consecutive patients with hypoxic respi-
ratory failure admitted to ICU to distinguish ALI/ARDS from
CHF.49 The median BNP was 325 pg/mL in the patients with
ALI/ARDS compared to 1260 pg/mL in the patients with
CHF. Using ROC curve analysis a cutoff level of less than
200 pg/mL had a specificity for ARDS of 91%, while a cutoff
level of more than 1200 pg/mL had specificity for CHF of
92%. Moreover, regardless of final diagnosis increased NPs
levels correlated with mortality. Furthermore, as previously
demonstrated,50 the correlation between BNP and pulmo-
nary capillary wedge pressure was poor. In another
prospective study51 high NT-proBNP levels were highly
associated with mortality in ICU patients with ARDS; they
were also associated with more profound organ failure, and
less ventilator-free days.Pleural fluid
Several small studies have explored the utility of measuring
NPs in pleural fluid to classify effusions as transudates or
exudates.52,53 In the study by Porcel et al.52 a cutoff of NT-
proBNP of 1500 pg/mL was highly specific and sensitive for
the diagnosis of CHF related pleural effusion, it was also
Table 2 Application of NP levels in pulmonary medicine.
Pulmonary
Embolism
Correlation of PE with RV dysfunction
Increased mortality
COPD Increased levels during exacerbations
Increased levels and need of ICU
Acute cardiac dysfunction during
weaning from mechanical
ventilation
Pulmonary
HTN
Detection of pulmonary HTN
Correlation with functional
impairment
ARDS Differential diagnosis with CHF
Mortality while on ICU
Pleural Fluid Detection of CHF related effusion
TACO/TRALI Aid in the diagnosis of TACO
Differential diagnosis of TACO vs. TRALI
Pulmonary
resection
Increased levels after surgery
CAP Correlation with pneumonia severity index
Brain natriuretic peptide measurement in pulmonary medicine 1773noted that this marker was not elevated in transudates
related to hepatic hydrothorax. These studies suggest that
measurement of NPs in the pleural fluid could be useful,
especially in effusions misclassified by Light’s criteria, as
seen in patients with CHF treated with diuretics. A more
recent study in 181 patients54 suggested that a pleural fluid
NT-proBNP and BNP has an area under the curve of 0.96 and
0.90, respectively, for diagnosing effusions due to CHF. The
cutoff values of 1300 and 115 pg/mL, respectively, for NT-
pro-BNP and BNP had the best discriminating properties.
TACO and TRALI
Transfusion related acute lung injury (TRALI) is a form of
permeability pulmonary edema seen after blood trans-
fusions and related to immune events55; transfusion asso-
ciated circulatory overload (TACO) is a type of cardiogenic
pulmonary edema seen as result of fluid overload in the
same clinical setting. The differentiation between these
two clinical entities is frequently challenging.56 In early
studies both BNP57 and NT-proBNP58 were compared in
patients with clinical suspicion of TACO and asymptomatic
controls. Both studies found elevations on NPs in the
patients with TACO.
In a more recent prospective cohort trial 59 both BNP and
NT-proBNP were higher patients with TACO than those with
suspected TRALI, however, there was a large overlap of
values. Median BNP was 375 pg/mL (interquartile range
[IQR], 123e781 pg/mL) in TRALI, 446 pg per mL (IQR,
128e743 pg/mL) in possible TRALI, and 559 pgpg/mL (IQR,
288e1348 pg/mL) in TACO patients (PZ 0.038). A number
of confounding factors including shock, left and right heart
dysfunction, hypoxemia and renal failure make it difficult
to distinguish between TACO and TRALI based on NPs levels
alone.
NPs after pulmonary resection
In a small study from Japan60 25 patients with lung cancer
underwent either lobectomy or pneumonectomy. The levels
of NPs were measured before and after the procedure. A
significantly greater increase was noted in the pneumo-
nectomy group. The authors ascribed the elevation of NPs
to the increase of mean pulmonary artery pressure and
total pulmonary vascular resistance seen in the post-
operative period. In an animal model,61 NPs were elevated
after pneumonectomy. In this study NPs were detected in
the endothelium of the pulmonary artery, suggesting in situ
production.
Community acquired pneumonia
Community acquired pneumonia (CAP) is a common infec-
tion with a large global impact. Risk stratification is an
important priority in the management of patients with CAP.
BNP levels were measured in the “Procalcitonin Guidance
of Antibiotic Therapy in Community acquired Pneumonia
(ProCAP) study”.11 In this study there was a significant
correlation between BNP and the Pneumonia Severity Index
(PSI). More importantly, BNP levels were significantly higherin non-survivors compared to survivors [median 439.2 (IQR
137.1e1384.6) vs. 114.3 (51.3e359.6) pg/mL 1, P< 0.001].
In a receiver operating characteristic analysis for the
prediction of survival the area under the curve (AUC) for
BNP was comparable to the AUC of the PSI (0.75 vs. 0.71,
PZ 0.52). The optimal cutoff for BNP was 279 pg/mL). As
reported in other studies, the BNP levels in this study were
much lower than those seen in patients with CHF.Other conditions
A recent paper62 described how elevated BNP and/or
echocardiographic markers of right heart dysfunction were
associated with increased mortality across different types
of interstitial lung disease. Ninety patients were followed
for 20 9 months; those with BNP higher than 20 pg/mL
had a 14 fold increased mortality when compared to those
with BNP less than 4 pg/mL.
A prospective study on 94 patients63 that underwent
cardiopulmonary exercise test found a cardiocirculatory
limitation in 27 (29%) patients. Median (interquartile range)
resting BNP [162 (45e415) vs. 39 (19e94) vs. 24 (15e46) pg/
mL; P< 0.001] and NT-proBNP [506 (129e1167) vs. 77
(35e237) vs. 34 (19e77) pg/mL; P< 0.001] were higher in
patients with cardiocirculatory as compared with those
with pulmonary limitation (nZ 28) and those without car-
diocirculatory or pulmonary limitation (nZ 39).Conclusions
The measurement of NPs for diagnostic and prognostic
purposes in patients with cardiovascular conditions has
been extensively studied. Less attention has been placed
on the role of NPs in patients with pulmonary conditions. As
seen in Table 2 in several well-defined groups of patients
with pulmonary disease NPs may provide the clinician with
useful diagnostic and prognostic information. A limitation
of the interpretation of NPs in pulmonary disease is the
1774 D. Salerno, P.E. Marikconfounding effect of concurrent conditions such as CHF,
hypoxia, sepsis and renal failure. While the diagnosis of CHF
using NPs is based on well-defined cutoff levels, the
differences in NP levels in patients with pulmonary condi-
tions are more subtle, but still have significant value for
diagnosis and risk stratification.
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